Milestone Pharmaceuticals (MIST) to Release Quarterly Earnings on Thursday

Milestone Pharmaceuticals (NASDAQ:MIST) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Milestone Pharmaceuticals Stock Up 5.7%

MIST stock opened at $1.67 on Tuesday. The stock has a 50-day simple moving average of $1.87 and a two-hundred day simple moving average of $2.00. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $3.06. The firm has a market capitalization of $142.23 million, a PE ratio of -2.04 and a beta of 0.48. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company lifted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Insider Activity at Milestone Pharmaceuticals

In other news, COO Jeffrey Edward Nelson sold 58,007 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $134,576.24. Following the transaction, the chief operating officer owned 41,993 shares of the company’s stock, valued at $97,423.76. This represents a 58.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joseph Oliveto sold 133,054 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28. Following the sale, the chief executive officer owned 450,667 shares in the company, valued at approximately $1,045,547.44. This trade represents a 22.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 416,327 shares of company stock worth $935,458 in the last 90 days. 19.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Cetera Investment Advisers bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $42,000. Invesco Ltd. purchased a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $44,000. Creative Planning raised its holdings in shares of Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in Milestone Pharmaceuticals by 30.1% in the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.